20 DECEMBER 2018
Sioux Falls, SD – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today, that it has raised $22 million in its Series A-2 round that closed December 15, 2018. The company plans to use the capital to accelerate its growth, continue expansion of its operations and advance its novel immunotherapy platform.
“This investment provides a significant boost to our capital strategy as we proceed to Phase 2 clinical trials and accelerate development of commercial targets for Type 1 diabetes, cancer and influenza,” said Eddie J. Sullivan, PhD, SAB’s president CEO and co-founder. > > >
18 DECEMBER 2018
Sioux Falls, SD – South Dakota Equity Partners (SDEP) today announced it has invested $1.05 million in SAB Biotherapeutics (SAB), a biopharmaceutical development company. The SAB investment is part of the company’s Series A-2 raise marking the first investment made by the new private equity fund focused on South Dakota growth-stage companies. The investment will boost SAB’s aggressive growth plans and capacity building to accelerate the advancement of the company’s novel immunotherapy platform.
“SAB Biotherapeutics is an outstanding first investment for SDEP,” said Blaine Crissman, President of South Dakota Equity. “SAB has achieved key milestones, proven a novel technology and production system, developed a robust product pipeline, assembled a strong team and outlined an aggressive plan and timeline for growth.” > > >
20 NOVEMBER 2018
“We’re excited to have such a large and impactful project to launch South Dakota’s first innovation community,” said Rich Naser, Jr., president and CEO of the USD Discovery District. “This $30.9 million project encompasses both a large multi-tenant research building and manufacturing facility, and is about three times larger than we anticipated 12 months ago.” > > >
28 AUGUST 2018
Sioux Falls, SD – SAB Biotherapeutics, Inc. (SAB) a clinical-stage biopharmaceutical development company, has received a $10 million investment from T. Denny Sanford as part of its Series A-2 raise. The businessman and philanthropist previously invested in SAB in 2014.
“SAB Biotherapeutics has made great strides in a relatively short timeframe,” Sanford said. “They have reached key milestones, collaborated with prominent partners, developed a robust product pipeline and are working on near-term solutions to health conditions like cancer and Type 1 Diabetes.” > > >
15 AUGUST 2018
Sioux Falls, SD – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases. The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, with United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Naval Medical Research Center (NMRC) and others. > > >
Sioux Falls, S.D., – The USD Discovery District and the Governor’s Office of Economic Development (GOED) announced today that
SAB Biotherapeutics and Alumend will become the innovation community’s anchor tenants.
The Discovery District, an 80-acre planned corporate and academic research park adjacent to the University Center in northwest Sioux Falls, will provide access to research facilities and infrastructure for research business development and foster collaboration for the commercialization of new technologies.
The $30.9 million project will encompass not only a large multi-tenant research building, but also South Dakota’s first commercial cGMP (Current Good Manufacturing Practice) biotherapeutics manufacturing facility, and is being made possible by an historic strategic and financing partnership among the State of South Dakota, the University of South Dakota (USD), the City of Sioux Falls, the Board of Regents and the business community through Forward Sioux Falls. > > >
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, has expanded its Vaccinology and Antibody Characterization (VAC) team with the promotion of Molly Bobbitt to VAC Manager and hiring of Seth Harris as Research Associate.
The VAC department works with the Tc Bovine both evaluating and maximizing the production of human antibodies to meet production criteria and levels. They also formulate the vaccines for the cattle from disease antigens and create the protocol for optimal production of human antibodies and health of the animals. In addition, the team analyzes the samples from pre-clinical studies and human clinical trials and generates data. > > >
Sioux Falls, S.D., and Salt Lake City, Utah – SAB Capra, LLC, a privately-held, emerging bioscience company developing targeted human polyclonal antibodies for use in diagnostics, testing and immunotherapeutics, has been awarded a $225,000 grant from the National Institutes of Health (NIH) to advance its novel immunotherapy platform targeting pandemic influenza in collaboration with Utah State University.
The company will use the funds, awarded through the National Institute of Allergy and Infectious Disease (NIAID), to continue development and optimization of its transchromosomal (Tc) goats™ to broaden the Tc animal platform developed by SAB Biotherapeutics, to small ungulate species. The award outlines evaluation of Tc goat produced human antibodies to fight the pandemic influenza (H7N9) with which the goats were vaccinated to generate the natural immune response. > > >
Sioux Falls, S.D., January 10, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced its anti-MERS immunotherapy (SAB-301) appears safe in a Phase I Clinical Trial. Results of the study, sponsored, funded and conducted by National Institutes of Health (NIH) were published today in
The Lancet Infectious Diseases.
Presently, there are no approved vaccines or treatments for Middle East respiratory syndrome (MERS)–
a newly discovered, contagious and sometimes fatal respiratory illness, caused by a virus known as MERS coronavirus (MERS-CoV). Since the first confirmed case in Saudi Arabia in 2012, the illness has spread to 27 countries and more than 2,000 people, with a fatality rate approaching 40%, according to the World Health Organization.
“This is the first study to show the safety of a potential treatment for MERS,” said John H. Beigel, M.D.,
a medical affairs scientist affiliated with Leidos Biomedical Research, supporting the NIAID Division of Clinical Research, and lead investigator on the study. “SAB-301–an experimental treatment for MERS developed from cattle plasma–was safe, well tolerated by healthy volunteers and had the same half-life as human-derived antibodies.” > > >
Sioux Falls, SD, December 21, 2017 – SAB Biotherapeutics (SAB),
a clinical-stage biopharmaceutical development company, announced today its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.
“This study provides the first clinical evidence showing the human polyclonal antibody therapeutic– produced from our natural DiversitAb immunotherapy platform–is safe, and provides an option for recalcitrant infection resistant bacteria where antibiotics and multiple other therapies were ineffective,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO.
“This is an important step in furthering the development of this platform technology in infectious disease, including anti-microbial resistance,” he continued. > > >
20 DECEMBER 2017
SAB Biotherapeutics launches Utah-based subsidiary SAB Capra, LLC.
Transgenic goats broaden application of premier immunotherapy platform
with personalized medicine, testing and diagnostics
Sioux Falls, SD, December 20, 2017 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced today they have formed and officially launched a Utah-based wholly owned subsidiary,
SAB Capra, LLC and incorporated the new entity under the SAB Biotherapeutics corporate umbrella. The new company leverages Transchromosomal (Tc) goats™ to produce human therapeutics and reagents for diagnostics and testing.
“We’re excited to launch this strategic complement to the SAB Biotherapeutics’ first-of-its-kind immunotherapy development platform,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics and SAB Capra. > > >
Sioux Falls, SD, October 5, 2017 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, today held a public groundbreaking to for their first-of-its-kind greenfield biopharmaceutical production pharm under construction in Lincoln County. SAB, founded in 2014, develops human antibody therapeutics utilizing plasma from transgenic cattle (TcBovine™).
“This is a historic day for SAB Biotherapeutics, South Dakota and the bioscience industry,” said SAB Biotherapeutics president, CEO and co-founder Dr. Eddie Sullivan. “We’re excited to be utilizing this cutting-edge science, so proud of our dedicated team and grateful for the confidence of our investors and support of our industry, state and community–enabling us to forge a new path and make a global impact on human health.”
The event, held at the construction site, brought together the entire lifecycle of the science culminated in the production pharm. It began with remarks from the technology’s founder Dr. James Robl who began working on the project turned company while a professor at the University of Massachusetts at Amherst in 1998. > > >
Sioux Falls, SD, August 3, 2017 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, announced today it is fully integrating operations with the construction of a first-of-its kind production pharm underway near its corporate headquarters.
SAB, founded in 2014, develops antibody therapeutics using its next generation immunotherapy platform utilizing plasma from transgenic cattle (TcBovine™). The TcBovine have been genetically designed to produce large amounts of natural human polyclonal antibodies when vaccinated against a disease. Animal antibodies have been made in rabbits, sheep, and horses for use in humans. However, SAB’s platform is the first to produce human antibodies in large animals (cattle).
The company’s first two products are in clinical trials with other infectious disease, oncology and autoimmune targets in development.
“As we continue to expand our operations to produce antibodies for additional disease targets, designing and operating our own production facility is a top priority,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics. “The pharm is a key component to owning the entire supply chain–from development through production–to improve efficiency and streamline operations while laying an important foundation for more rapid and expansive growth.” > > >
Sioux Falls, SD, August 3, 2017 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today the appointment of William J. Polvino, M.D. to its business advisory board.
Dr. Polvino is a pharmaceutical entrepreneur with more than 26 years of experience in the healthcare arena. He is currently the CEO of Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic.
“SAB has been working with Dr. Polvino through various industry connections. He has been a champion in advancing our immunotherapy platform,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics. “We are thrilled to have him join us in a more formal capacity as we forge a path with our powerful polyclonal platform.” > > >
Sioux Falls, SD, April 26, 2017 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today announced that Thorkil Kastberg Christensen has joined their Board of Directors. SAB, which was founded in 2014, develops human antibody therapeutics using its first-of-its-kind immunotherapy platform.
Christensen brings to SAB decades of global business strategy and execution as former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about US $40 billion. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations. > > >
Sioux Falls, SD, – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today officially announced the hire of Christoph L. Bausch, Ph.D. as its Chief Science Officer (CSO).
Dr. Bausch joins SAB’s executive team as an experienced research scientist and business development executive who has led the successful discovery, development and commercialization of platform technologies. Former CSO, Dr. Jin-an Jiao, who helped establish SAB’s technology, has transitioned to a strategic consultant role for the company. > > >
20 SEPTEMBER 2016
SAB Biotherapeutics' Immunotherapy Proposal Among Top Platform Technology Solutions in Recent WHO Report
Platform leveraging transchromosomic cattle shows promise for global response to epidemics
Bethesda, MD and Sioux Falls, SD, – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine™), was identified as of one of the six most meritorious proposals emerging from the World Health Organization (WHO) Public consultation on platform technologies for priority infectious diseases with epidemic potential.
This consultation was part of the WHO Research & Development Blueprint, a global strategy and preparedness plan that allows the rapid activation of R&D activities that can be used to save lives and avert large-scale crisis during epidemics. SAB Biotherapeutics’ technology was the only immunotherapy platform among the six finalists (of 35 proposals), which also included three vaccine platforms, a diagnostic technology and a technology covering all product streams. > > >
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today it has received a Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for up to $1.42 Million to advance its treatment for influenza. The funding–specifically for the production and preclinical testing of its novel antibody therapeutic targeting influenza viruses–is a research collaboration project with the University of South Dakota (USD) Sanford School of Medicine. The project was initiated through the BioSNTR, a distributed research initiative that facilitates academic and industry research collaborations to advance biotechnology and commercialize innovations. > > >
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today that it has been awarded a contract for up to $5.3 million by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS). The funding will be used for advanced clinical manufacturing and testing for SAB’s novel antibody therapeutic (SAB-301) to treat MERS-CoV. > > >
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today that Phase I Clinical Trials are underway for its human antibody treatment (SAB-301) for MERS-CoV. The goal of the study–sponsored, funded and conducted by National Institutes of Health (NIH)–is to evaluate the dosage and safety of this new therapeutic. > > >
Baltimore, MD., – In a new study, University of Maryland School of Medicine researchers have had promising results with a new treatment for Middle East Respiratory Syndrome (MERS). The study, published today in the journal Science Translational Medicine, found a new treatment that protected mice from MERS infection. > > >
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, focused on advancing some of the most innovative molecular genetics and human antibody technology in the world, today announced the appointment of four internationally respected immunotherapy specialists to its newly formed Scientific Advisory Board. > > >
Sioux Falls, S.D.,—The Sioux Falls Development Foundation is announcing a $3 million equity investment in Sioux Falls-based SAB Biotherapeutics to help grow its unique disease-fighting platform. > > >
3 DECEMBER 2014
SAB Biotherapeutics and U.S. Army team up to treat Hantavirus
Human antibodies produced in genetically designed cows can protect against deadly diseases
Sioux Falls, S.D., – SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, has teamed up with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Their work, published in the November 26, 2014 online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens, including hantavirus. > > >
Fort Detrick, MD – Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today’s online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. > > >
A small biomedical company has engineered a way for cows to produce large quantities of human antibodies to fight infectious disease. Although the technology won’t be available for perhaps three to five years, it could be a new method to address such infectious diseases as influenza, Ebola, Zika and Middle East respiratory syndrome (MERS).
The technology, devised by SAB Biotherapeutics, a privately held company in Sioux Falls, South Dakota, followed the same principle used in a handful of cases during the Ebola outbreak. Physicians took plasma from convalescent patients and gave it to sick patients. That worked well in a few cases, but a few patients can’t provide enough plasma to counter a widespread outbreak.
Cows might offer a solution: A cow can produce 30 to 60 liters of concentrated antibodies per month–enough to potentially treat several hundred patients. Humans, on the other hand, are not as industrious—a patient can produce only 4 liters per month, enough to treat about three people. > > >
4 OCTOBER 2016
COWS ENGINEERED WITH HUMAN GENES COULD STOP OUR NEXT DISEASE OUTBREAK
Cattle that can crank out human antibodies are being tested as a first line of defense against infectious diseases.
During the most recent Ebola outbreak in West Africa, health-care workers treated some sick patients by injecting them with plasma—the translucent part of the blood—taken from individuals who had survived the disease. In the absence of an approved drug to treat patients, the hope was that protective proteins in the donor plasma would help recipients fight the disease and recover.
A biotech company wants to use this same approach to treat a variety of infectious diseases, with one key difference: cows, not humans, will be the plasma donors. > > >
Leaders from Sioux Falls-based SAB Biotherapeutics are traveling to Saudi Arabia next week for talks with the Saudi government that might lead to a clinical trial related to the country’s outbreak of Middle East Respiratory Syndrome, or MERS. > > >
26 NOVEMBER 2014
GMO Cattle Produce Serum to Fight Hantavirus – Is Ebola Next?
NBC News, By Maggie Fox
Dr. Kent Brantly donated a gallon or more of his own blood serum to help treat other patients with Ebola. Now, researchers say they've used genetically engineered cattle to do something similar.
Serum from the cattle has been used to treat hantavirus — a rare but highly deadly virus that causes regular outbreaks, including one that killed three campers at Yosemite National Park in 2012. > > >
Humans have been using antibody therapies to treat infectious disease for more than 100 years. Blood plasma from influenza survivors administered to sick patients in 1912 may have contributed to their dramatic turnaround. In the years since, immune proteins from survivors have been administered to infected individuals in an attempt to combat diseases like Lassa fever, SARS, and even Ebola.
It’s hard, however, to find survivors who can donate plasma containing these lifesaving immune proteins. Now, a team led by researchers at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Frederick, Maryland, has used genetically engineered cows to produce large amounts of human antibodies against hantavirus, an often deadly disease mainly transmitted from rodents to people. > > >
26 NOVEMBER 2014
Human Antibodies Produced in DNA-Vaccinated Cows Protect
in Lethal Models of Hantavirus
Medical Xpress, US Army Medical Research Institute of Infectious Diseases
Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. Their work, published in today's online edition of Science Translational Medicine, provides proof of concept for producing antibodies against a broad range of human pathogens. > > >
SAB Biotherapeutics, Inc. Producing Human Antibodies to Combat Disease
Broader Research Community a South Dakota Advantage
While using animals to produce human antibodies may have sounded like a work of science fiction
in the not-too-distant past, that’s exactly what one South Dakota company – SAB Biotherapeutics, Inc. is currently doing. > > >
Animal Biotech industry Thrives in State's Climate
In labs throughout Sioux Falls region, scientists are working
to come up with next great discoveries to cure diseases
Sioux Falls, South Dakota – On a farm near Flandreau, miniature pigs are genetically engineered to have human diseases. In a pasture near Canton, sheep with no genetic modifications are raised for medical testing. Across the border in Iowa, cows in a stress-free environment are cloned and genetically engineered to produce human antibodies. Their job is to donate plasma a few times a month. In labs throughout the Sioux Falls region, scientists are working to come up with the next great discoveries to cure diseases and help people live better lives. > > >
SAB Biotherapeutics Brings New Technology to BIO
Sioux Falls, South Dakota – Attendees at BIO will have a glimpse of a new technology from SAB Biotherapeutics, Inc. (SAB) that can revolutionize the way diseases are treated and even prevented.
> > >
Game-Changing Technology Nears Clinical Stage
World’s First Large Animal Platform to Produce Fully Human Antibodies
It is not often that something genuinely novel comes along to completely transform an approach,
a treatment, a complete perspective…and truly a world of possibility. It’s called a game changer.
The new technology from SAB Biotherapeutics, Inc. (SAB) is just that. > > >